Ohio State Navbar

Research Programs

Completed Trials


Below is a list of recently completed clinical trials.

Adult ADHD:

Protocol CRIT124D2302 A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD.

Protocol CRIT124D2302E1 A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD.


Anxiety:

Protocol A5361017: “A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder.”

Research study of an investigational medication for generalized anxiety disorder in adults ages 18-65.

Protocol A5361022: "A Phase 3, 52-Week Open-Label Long-Term Safety and Tolerability Study of PD 0332334 in subjects with Generalized Anxiety Disorder."

Research study of an investigational medication for adults 18 and up.

Protocol LUAA21004_309: "A Phase 3 Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of LU AA21004 in Acute Treatment of adults with Generalized Anxiety Disorder.

Research study of an investigational medication for adults 18 and up.

Bipolar Depression:

Protocol A1281158: "A Six-Week, Double-Blind, Multicenter, Placebo- Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone as add-on, Adjunctive Therapy with Lithium, Valproate or Lamotrigine in Bipolar I Depression."

Research study of the effectiveness and safety of Ziprasidone in combination with a mood stabilizer (lithium, valproate or lamotrigine) for treatment of Bipolar I depression who are at least 18 years of age.

Child ADHD:

Protocol SPF503-313: "A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents, 6-17 years of age who have been diagnosed with ADHD.

Protocol SPD503-312. Phase 3, Double-blind, Randomized, Multi-center, Placebo-controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once-daily Dosing with Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD).

Child Bipolar Disorder:

 Protocol SCA102833: The Evaluation of LAMICTAL™ as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age.

Depression:

Protocol CAGO178C2301 An 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5 mg and 1 mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD).      

Protocol CAGO178C2399: “A 52-week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with Major Depressive Disorder (MDD).”

This investigational drug is the first in a new class of antidepressants which targets melatonin for adults 18-70 years of age.

Protocol PKI113009: “A six-week randomized, double-blind, multi-center, placebo-controlled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.” Research study for subjects 18-60 year old, currently depressed who had at least one previous episode of depression.